Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) was up 4.1% during trading on Tuesday . The company traded as high as $11.39 and last traded at $11.28, with a volume of 156,972 shares. The stock had previously closed at $10.84.

A number of equities research analysts have commented on VTAE shares. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Vitae Pharmaceuticals in a research report on Tuesday, March 29th. BMO Capital Markets started coverage on Vitae Pharmaceuticals in a research report on Monday, April 11th. They set an “outperform” rating and a $15.00 price objective for the company. Zacks Investment Research upgraded Vitae Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.25 price objective for the company in a research report on Thursday, May 5th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Vitae Pharmaceuticals in a research report on Friday, June 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Vitae Pharmaceuticals has an average rating of “Buy” and a consensus price target of $16.65.

The stock’s 50 day moving average is $10.43 and its 200 day moving average is $8.79. The stock’s market capitalization is $322.15 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.07. The business earned $0.05 million during the quarter. During the same quarter last year, the firm posted ($0.47) EPS. The business’s revenue was down 66.7% on a year-over-year basis. Equities research analysts anticipate that Vitae Pharmaceuticals Inc. will post ($1.74) earnings per share for the current year.

An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP acquired a new stake in shares of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned 0.34% of Vitae Pharmaceuticals at the end of the most recent reporting period.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.